Mindfulness for patients with difficult-to-manage asthma

Investigating the impact of a short-course MBSR-based mindfulness intervention on patients with difficult-to-manage asthma

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN24452721

Enrollment

Registered

2016-01-13

Start date

2015-01-13

Completion date

Unknown

Last updated

2017-07-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Topic: Primary Care, Respiratory disorders

Interventions

At baseline, participants provide informed consent and complete a battery of self-report questionnaires and computerized measures and routinely-collected clinic data will be collected during routine p

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Aged 18 years or over 2. Confirmed diagnosis of Asthma 3. Under the care of the Difficult Asthma Clinic at Southampton General Hospital (University Hospital Southampton NHS Foundation Trust) 4. Positive screening score for anxiety (greater than 8 on the HADS hospital anxiety and depression scale)

Exclusion criteria

Exclusion criteria: 1. Under 18 years of age 2. Comorbid psychological disorders other than anxiety/depression measured using MINI Neuropsychiatric Interview questionaire 3. Acute exacerbation of asthma needing course of oral steroid or increased dose of maintenance steroid within 28 days of first intervention session 4. Current participation in an additional asthma intervention study

Design outcomes

Primary

Measure	Time frame
Asthma-related quality of life is measured using the Asthma Quality of Life Questionnaire (AQLQ) at baseline and 3 months post-test.	—

Secondary

Measure	Time frame
1. Asthma control is measured using The Asthma Control Test (ACT) at baseline and 3 months post-test 2. Anxiety and depression is measured using The Hospital Anxiety and Depression Scale (HADS) at baseline and 3 months post-test 3. Mindfulness is measured using the Mindful Attention Awareness Scale (MAAS) at baseline and 3 months post-test 4. Anxiety is measured using the Spielberger Anxiety Inventory (STAI) at baseline and 3 months post-test 5. Hyperventilation syndrome is determined using the Nijmegen Questionnaire (NQ) at baseline and 3 months post-test 6. Medication adherence is measured using the Medication Adherence Report Scale for Asthma (MARS-A) at baseline and 3 months post-test 7. Degree of airway inflammation and to confirm that psychological benefits are independent from lung-function improvement are determined by measuring the level of exhaled nitric oxide 8. Potential dose-response of mindfulness is measured using self-reporting in weekly diaries 9. Cognitive measures of attention including versions of the dot-probe task (8-minutes) and the attention network test (8 minutes) are completed at baseline and 3 months post test 10. Acceptability of the intervention is measured using in-depth discussions with focus groups 6 weeks post-test	—

Measure

Time frame

1. Asthma control is measured using The Asthma Control Test (ACT) at baseline and 3 months post-test 2. Anxiety and depression is measured using The Hospital Anxiety and Depression Scale (HADS) at baseline and 3 months post-test 3. Mindfulness is measured using the Mindful Attention Awareness Scale (MAAS) at baseline and 3 months post-test 4. Anxiety is measured using the Spielberger Anxiety Inventory (STAI) at baseline and 3 months post-test 5. Hyperventilation syndrome is determined using the Nijmegen Questionnaire (NQ) at baseline and 3 months post-test 6. Medication adherence is measured using the Medication Adherence Report Scale for Asthma (MARS-A) at baseline and 3 months post-test 7. Degree of airway inflammation and to confirm that psychological benefits are independent from lung-function improvement are determined by measuring the level of exhaled nitric oxide 8. Potential dose-response of mindfulness is measured using self-reporting in weekly diaries 9. Cognitive measures of attention including versions of the dot-probe task (8-minutes) and the attention network test (8 minutes) are completed at baseline and 3 months post test 10. Acceptability of the intervention is measured using in-depth discussions with focus groups 6 weeks post-test

—

Countries

United Kingdom

Contacts

Public ContactMegan Liddiard

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026